Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-018116

CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $21.40 ($267,458)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-06-20 Sale : show line 1 in the form 10b5-1 −12,500 $21.40 $267,458 965,188 I
Open-market sales · 12,500 sh · avg $21.40 · $267,458
Loading xslF345X05/form4-06242025_090617.xml…